Its nanoformed drug product Glioblastoma enables highly promising in-vivo data
Nanoform, an innovative nanoparticle medicine enabling company, together with TargTex, a European biotech company, are set to present in-vivo data, enabled by nanoformed drug product for the treatment of Glioblastoma.
This data was generated for a planned Phase1/2a clinical trial, due to commence in early 2024.
The presentation at 10:00am EDT on 25 October at PODD Conference (Partnerships and Opportunities in Drug Delivery) in Boston, USA, will be given by Dr João Seixas, CEO, TargTex and Christian Jones, CCO, Nanoform.
In a space where unfortunately no significant advances were seen in the latest two decades, this novel approach provides hope for patients, and I wish we had started this collaboration with Nanoform sooner
News of Nanoform’s PoC success and subsequent GMP Agreement with TargTex was published in February 2022. Since then, the companies have further collaborated in the optimization of a hydrogel formulation for implantation at the site of the resected tumor. This process demands very small particles to increase drug loading and improve release profile. Other technologies and approaches previously failed to deliver the necessary performance.
“In a space where unfortunately no significant advances were seen in the latest two decades, this novel approach provides hope for patients, and I wish we had started this collaboration with Nanoform sooner,” Dr João Seixas, CEO, TargTex.
“We are thrilled that Nanoform’s platform technologies are able to help this highly promising medicine reach the clinic,” said Professor Edward Hæggström CEO, Nanoform.